ライフサイエンスコーパス: drug therapy

1 ructure that may represent prime targets for drug therapy.

2 f laboratory correlates of human disease and drug therapy.

3 al target class of fundamental importance in drug therapy.

4 derivatives may have potential for glaucoma drug therapy.

5 jor unmet target for a vaccine and antiviral drug therapy.

6 eligible persons could receive sofosbuvir 3-drug therapy.

7 e might represent more tractable targets for drug therapy.

8 a molecular justification for combinatorial drug therapy.

9 ess disease progression and effectiveness of drug therapy.

10 with loss of Casq2 and test mechanism-based drug therapy.

11 ely to benefit from immediate anti-epileptic drug therapy.

12 As such they are attractive targets for drug therapy.

13 dings suggest evaluation of TLR3 agonists in drug therapy.

14 an circumvent the immune response and escape drug therapy.

15 hat are essential for the development of new drug therapy.

16 mber aberrations associated with response to drug therapy.

17 ein 78 kDa (GRP78) was utilized for targeted drug therapy.

18 xisting antihyperglycemic and cardiovascular drug therapy.

19 HDCA is a candidate for antiatherosclerotic drug therapy.

20 use in predicting the effects of combination drug therapy.

21 uring their disease course, and 82% received drug therapy.

22 c or acquired resistance to topo II-targeted drug therapy.

23 eased in several diseases and by concomitant drug therapy.

24 r related to sex, coexisting conditions, and drug therapy.

25 eye disease that requires effective topical drug therapy.

26 on of this population is primarily driven by drug therapy.

27 r heart failure compared with antiarrhythmic drug therapy.

28 ically validated class of targets for cancer drug therapy.

29 cogenic events is amenable to targeting with drug therapy.

30 ognition in the context of anti-dopaminergic drug therapy.

31 lassical monoamine oxidase inhibiting (MAOI) drug therapy.

32 ic lesions could be important for optimizing drug therapy.

33 ospitalizations compared with antiarrhythmic drug therapy.

34 evaluate the pharmacodynamics of dual phage-drug therapy.

35 ants likely up-selected and down-selected by drug therapy.

36 ling and to monitor the efficacy of anti-RAS drug therapy.

37 ctor of the effectiveness of anti-arrhythmic drug therapy.

38 , and potentially to tailor patient-specific drug therapy.

39 absence of treatment and even more so during drug therapy.

40 f functional interference of ATP6AP2 through drug therapy.

41 Toxoplasma gondii cyst stage is resistant to drug therapy.

42 ptor proteins and the most common targets of drug therapy.

43 d serve as an ideal target for otoprotective drug therapy.

44 nce the management of patients on antifungal drug therapy.

45 DM) for improving the efficacy and safety of drug therapy.

46 ession is altered by disease development and drug therapy.

47 own about how resistant clones evolve during drug therapy.

48 se receiving an escalation in antiarrhythmic drug therapy.

49 tor (ICD) is frequent despite antiarrhythmic drug therapy.

50 y of an adverse drug reaction resulting from drug therapy.

51 among those aged 66 years or older, relevant drug therapies.

52 and novel molecular targets for anti-cancer drug therapies.

53 djunct host-directed cellular and repurposed drug therapies.

54 tudy disease mechanisms as well as potential drug therapies.

55 isease severity and efficacy of vaccines and drug therapies.

56 ns in human serum, that determine dosages in drug therapies.

57 in drug response is a central feature of all drug therapies.

58 ], pyrazinamide, and ethambutol, among other drug therapies.

59 and continues to inspire the search for new drug therapies.

60 ate its use for both intravenous and inhaled drug therapies.

61 ance imposes a continuous threat to existing drug therapies.

62 ins is critical to the success of biological drug therapies.

63 erate human disease models and provide novel drug therapies.

64 e of the cerebrospinal fluid and other older drug therapies.

65 ese subunits may be useful in anti-influenza drug therapies.

66 d represents a potential target in antiviral drug therapies.

67 ffective antiparkinsonian and antidyskinetic drug therapies.

68 elling and simulation to predict alternative drug therapies.

69 ontinuation of potential trigger factors and drug therapies.

70 , and aid in the development of new targeted drug therapies.

71 ge-guided surgery, and theranostic PEGylated drug therapies.

72 inhibitors and to assess effects of combined drug therapies.

73 using iPSC-CM to personalize antiarrhythmic drug therapy?

74 than nonusers the year before initiating ED drug therapy (214 vs. 106 annually per 100,000 persons;

75 e adverse events were mainly associated with drug therapy (25.6%), surgery (23.7%), diagnosis (12.4%)

76 Thirty-eight RCTs (41.3%) evaluated drug therapy, 39 (42.4%) evaluated device therapy, and 1

77 lementing ablation with concurrent liposomal drug therapy, a complete and durable response was obtain

78 Compared to drug therapy, a resurgence of interest in using diet to

79 odynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal

80 ing pathway can contribute to development of drug therapy addressing aberrations in that pathway.

81 onal and glial signaling is accomplished via drug therapy/administration, although they frequently fa

82 and adequate empirical and definitive single-drug therapy (AESD, ADSD).

83 es of VT control and need for antiarrhythmic drug therapy after endocardial (ENDO) and adjuvant epica

84 or identifying new drugs for multifunctional drug therapy against acute organophosphorus poisoning.

85 ated proteins may serve as novel targets for drug therapy aimed at improving beta-cell function for t

86 igational (eg, JAK inhibitors, pomalidomide) drug therapy, allogenic stem cell transplantation with r

87 Acquired resistance to cancer drug therapies almost always occurs in advanced-stage pa

88 for recurrence, is better than conventional drug therapy alone for prevention of postoperative Crohn

89 highlight the progress that has been made in drug therapies and delivery systems, and also cell-based

90 mising biological findings to novel approved drug therapies and discuss the attendant challenges and

91 translational pharmacological studies of new drug therapies and provide evidence for engagement of th

92 COPD) is the primary testing methodology for drug therapies and studies on pathogenic mechanisms of d

93 de insight into the mechanistic link between drug therapies and systems-level off-target effects whil

94 nd a systolic BP threshold for initiation of drug therapy and a therapeutic target of <150 mm Hg in t

95 after adjustment for maternal antiretroviral drug therapy and baseline BMI.

96 of biochemical targets has brought to single-drug therapy and creates a statistical and experimental

97 viously shown that a specific combination of drug therapy and left ventricular assist device unloadin

98 s on recently published studies that support drug therapy and lifestyle modification of high risk pat

99 d allowed for optimization of antiarrhythmic drug therapy and reablation if necessary.

100 receptors (GPCRs) play an important role in drug therapy and represent one of the largest families o

101 metabolic liver disorders are refractory to drug therapy and require orthotopic liver transplantatio

102 After discontinuation of all anti-TNF drug therapy and the addition of methotrexate sodium, hi

103 y, and assess the efficacy of antiarrhythmic drug therapy and/or ablation procedures.

104 dying disease mechanisms, for development of drug therapies, and for fabrication of tissue equivalent

105 egimens including combination CVD preventive drug therapy, and (4) simplified delivery of healthcare

106 rug hypersensitivity may deprive patients of drug therapy, and occasionally no effective alternative

107 P<7.3e-5) and confounding factors, including drug therapy, and renal and hepatic impairment.

108 Patients vary in their responses to drug therapy, and some of that variability is geneticall

109 dications are initiation, step-up of current drug therapy, and straight substitution of individual dr

110 Current ablation and drug therapy approaches to treating AF are largely based

111 Drug therapies are able to help a small fraction of the

112 Combination drug therapies are considered the ideal treatment for in

113 Combination drug therapies are employed to treat patients with HIV,

114 ctive vaccine against infection, and current drug therapies are fraught with problems, predominantly

115 Current drug therapies are limited by toxicity and difficult tre

116 Newer targeted drug therapies are promising and are being examined in t

117 Available drug therapies are unsuccessful because they fail to pen

118 Antiretroviral drug therapy (ART) effectively suppresses replication of

119 quency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients with pa

120 radiofrequency ablation with antiarrhythmic drug therapy as first-line treatment in patients with pa

121 gh much of their impact can be controlled by drug therapy as with prokaryotic microorganisms, the eme

122 ications and non-steroidal anti-inflammatory drugs therapy) as well as 4 dietary exposures (folate, v

123 -of-care solution for the personalization of drug therapies, as well as for pharmacokinetic studies i

124 nfections cannot be completely eradicated by drug therapy, as the virus persists in reservoirs.

125 arrhythmia recurrence and off antiarrhythmic drug therapy at the end of the 12-month follow-up.

126 Receiving immunosuppressive drug therapy at the time of presentation was associated

127 ne (I-PTH) is the only FDA approved anabolic drug therapy available for the treatment of osteoporosis

128 provide new evidence of the optimization of drug therapy before percutaneous carotid intervention.

129 ation (CA) when compared with antiarrhythmic drug therapy both as first- and second-line therapy for

130 Errors in intravenous (IV) drug therapies can cause human harm and even death.

131 ndscape of multidrug resistance, alternating-drug therapy can slow evolution by constraining the muta

132 ed during 7 mo of combination antiretroviral drug therapy (cART).

133 elivery, and the current status of antisense drug therapy clinical trials for gastrointestinal-relate

134 play an increased resistance to conventional drug therapies compared with SOX11(-) MCL cells.

135 is review, the risk-benefit ratios of modern drug therapy compared with HCT in MF patients are analyz

136 do not respond to appropriate antiepileptic drug therapy consisting of 2 or more medications.

137 Antimalarial drug therapies containing artemisinins, 'ACTs', have bec

138 The influences of baseline calcification and drug therapy (dalcetrapib vs. placebo) on progression of

139 include volume replenishment, antiarrhythmic drug therapy, defibrillators, and adjustment of left ven

140 ells raises the possibility of their use for drug/therapy delivery.

141 Simulations suggest that drug therapies designed to reduce electrotonic coupling

142 In contrast, use of immunosuppressive drug therapy did not increase such risk.

143 Drug therapy did not significantly reduce epistaxis freq

144 After drug therapy discontinuation, 5 patients experienced out

145 Current antiretroviral drug therapies do not cure HIV-1 because they do not eli

146 vides possibilities to fine tune TRPA1-based drug therapies (e.g., for treatment of pain associated w

147 ely to receive rhythm control antiarrhythmic drug therapy, electric cardioversion, or catheter ablati

148 hmic medications or escalated antiarrhythmic drug therapy (escalated-therapy group).

149 gy-related adverse drug reactions, and multi-drug therapies, especially cancer combination therapy, m

150 confined to (radio) surgery and no targeted drug therapies exist.

151 imes treat recalcitrant diseases when single-drug therapies fail.

152 l be critical for more effective combination drug therapies for acute myeloid leukemia (AML).

153 iency with diabetes, metabolic syndrome, and drug therapies for cancer and cardiovascular diseases.

154 ons to eye movements might help in designing drug therapies for human eye movement dysfunctions such

155 SCD syndromes, which has led to several new drug therapies for patients with genetic arrhythmia synd

156 ilitate the development of new antibacterial drug therapies for treatment of hospital-acquired and ve

157 d in the disease to guide clinical trials of drug therapy for advanced thyroid cancers.

158 Caffeine citrate or placebo until drug therapy for apnea of prematurity was no longer need

159 No significant changes were observed in drug therapy for asthma or their comorbidities nor in th

160 s associated with traditional small-molecule drug therapy for cancer and to achieve both therapeutic

161 cting risk and individualizing lifestyle and drug therapy for cardiovascular prevention.

162 lecular pathway is the target of our current drug therapy for DFSP, imatinib, a tyrosine kinase inhib

163 We will discuss drug therapy for diabetes relative to CV risk, briefly s

164 Furthermore, assessment of optimal drug therapy for each ethnic group is needed.

165 ce mutations diminishes the effectiveness of drug therapy for HIV/AIDS.

166 vides a perspective on the current status of drug therapy for invasive fungal diseases, together with

167 Current drug therapy for metastatic renal cell cancer (RCC) resu

168 this Series paper, we trace the evolution of drug therapy for osteoporosis, which began in the 1940s

169 Metformin is the recommended initial drug therapy for patients with type 2 diabetes mellitus

170 od of positive outcomes of published RCTs of drug therapy for RA, and industry-funded RCTs performed

171 Our data support a delayed and non-invasive drug therapy for stroke.

172 Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventr

173 elivery of chitosan-alginate NP-encapsulated drug therapy for the treatment of dermatologic condition

174 A major obstacle that hampers the design of drug therapy for traumatic brain injury is the incomplet

175 V(5), and aVF) recorded before initiation of drug therapy from patients enrolled in the PRECEDENT (Pr

176 en compared with those in the antiarrhythmic drug therapy group (relative risk, 2.04; 95% confidence

177 ntly lower in the ablation group than in the drug-therapy group (90th percentile, 9% vs. 18%; P=0.007

178 In the drug-therapy group, 54 patients (36%) underwent suppleme

179 nificant difference between the ablation and drug-therapy groups in the cumulative burden of atrial f

180 Drug therapy has largely been abandoned, and defibrillat

181 effects associated with traditional systemic drug therapies, has presented a major hurdle for the dev

182 Molecularly targeted drug therapies have revolutionized cancer treatment; how

183 n the specific medication, dose, concomitant drug therapy, ICU setting, and patient-specific comorbid

184 strategies for the development of localized drug therapies in AC.

185 e, host-pathogen interactions and antifungal drug therapies in both the clinic and agriculture.

186 A challenge for drug therapy in ACH is targeting agents to the avascular

187 in some cases initiation of cardioprotective drug therapy in asymptomatic women.

188 CA seems to be superior to antiarrhythmic drug therapy in drug naive, resistant, and intolerant pa

189 Response to drug therapy in individual colorectal cancer (CRC) patie

190 re were differences in the immunosuppressant drug therapy in monotherapy as well as two to three drug

191 duce the mortality risk compared with single-drug therapy in PA bloodstream infections.

192 pregnancy, laying a foundation for improved drug therapy in pregnant women.

193 factors associated with response to biologic drug therapy in psoriatic patients.

194 These findings may inform decision making on drug therapy in status epilepticus and help develop safe

195 ve implications for tailoring individualized drug therapy in the future.

196 of previous studies that found no benefit of drug therapy in the treatment of BKN in kidney transplan

197 ntially be applied to follow the efficacy of drug therapy in the treatment of MGD.

198 y cited reasons for this absence of specific drug therapies include the heterogeneity of patients wit

199 which can be suppressed through combination drug therapy, including non-obvious drug combinations.

200 Triple-drug therapy induced >2-log reductions in microfilaria l

201 ve cohort study agreed to have their oral RA drug therapy intake electronically monitored using the M

202 s should understand and anticipate potential drug-therapy interactions of targeted temperature manage

203 Response to conventional drug therapies is modest.

204 the pharmacokinetic properties for existing drug therapies is necessary.

205 Anti-arrhythmic drug therapy is a frontline treatment for atrial fibrill

206 Resistance to current drug therapy is an important issue in the treatment of e

207 When drug therapy is contemplated and when the metabolic synd

208 Antiarrhythmic drug therapy is generally recommended as a first-line th

209 The efficacy of antiarrhythmic drug therapy is incomplete, with responses ranging from

210 -term maintenance of hemodynamic response to drug therapy is mainly restricted to patients with alcoh

211 The issue of resistance to targeted drug therapy is of pressing concern, as it constitutes a

212 Standard 14-day triple-drug therapy is preferable to 5-day concomitant or 10-da

213 Triple-drug therapy is safe and more effective than DEC + ALB f

214 sting is not routinely performed, and single-drug therapy is used for the treatment of most infection

215 efficacy of several interventions, including drug therapy, is increasingly established.

216 t 2 decades, as well as the significance for drug therapy, is reviewed subsequently.

217 important complication of immunosuppressive drug therapy (ISDT).

218 Drug therapies known to alter advanced lipoprotein analy

219 Resistance to current drug therapy limits treatment options in many HIV-1-infe

220 Immunosuppressive drug therapy lowered the risk of visual loss, independen

221 , to provide novel insights into disease and drug therapy mechanisms, and potentially to tailor patie

222 to either cryoballoon ablation (n = 163) or drug therapy (n = 82).

223 e regarded as excellent targets for chemical drug therapy of carcinomas.

224 MEM16A-targeted activators may be useful for drug therapy of cystic fibrosis, dry mouth, and gastroin

225 and are potential development candidates for drug therapy of hypertension, pain, diarrhea, and excess

226 safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazin

227 us, in future work, to investigate targeted drug therapy of tumours.

228 Focus on optimal preventive drug therapy of vascular risk factors and management sho

229 rstanding of underlying causes and effective drug therapies offered by recent work.

230 rove the efficiency of the evaluation of new drug therapies on atherosclerosis and cardiovascular dis

231 ge randomized clinical trials have evaluated drug therapy on HDL-C and cardiovascular outcomes.

232 or patients who do not do well with standard drug therapy or for those who prefer a disease-modifying

233 ontrol viral replication in conjunction with drug therapy or in rare cases spontaneously, most antivi

234 s persistence in individuals under effective drug therapy or those who spontaneously control viremia

235 states, such as cancer, and are modulated by drug therapies, our understanding of how such changes sh

236 4.3% vs 34.1% in those who received combined drug therapy; P = .02).

237 No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-

238 nly encountered neurotoxicants from prenatal drug therapy, pesticides, or tobacco.

239 RBC redox status responds in the context of drug therapy, physiologic stressors and pathologic state

240 esistance and the restricted pipeline of new drug therapies pose considerable risks to global health

241 abases were searched to identify original RA drug therapy RCTs published in 2002-2003 and 2006-2007.

242 Drug therapy reduces this impairment, and AR patients sh

243 96 (65%) patients who were on antiarrhythmic drug therapy (relative risk, 0.40; 95% confidence interv

244 yndromes (MDS) and its impact on response to drug therapy remain poorly understood.

245 anisms of de novo and acquired resistance to drug therapy remains a central challenge in the clinical

246 carotid endarterectomy combined with optimal drug therapy remains the standard of care for symptomati

247 g to cancer, and give an overview of current drug therapies selectively targeting the UPS.

248 Drug therapy should be avoided during the first trimeste

249 here was no history of head trauma, surgery, drug therapy, smoking, or alcohol abuse, nor was there a

250 eir disease respond poorly to anticonvulsant drug therapy, suggesting a need for new therapeutic targ

251 management of the surgical patient to guide drug therapy, surgical strategy, and medical management.

252 n blood pressure, adiposity, liver function, drug therapy, symptoms, or quality of life, except that

253 ure is available for OI and to develop novel drug therapies, taking advantage of a repositioning stra

254 V or its derivatives may be useful in future drug therapies targeting the NS3/4A protease.

255 An alternative approach to drug therapy targeting transcription factors driving the

256 scular permeability and is amenable to rapid drug therapy testing.

257 ic system represents an important target for drug therapies that may improve GI inflammation and its

258 use of severe long-term disability yet lacks drug therapies that promote the repair phase of recovery

259 these studies provide a rationale for using drug therapies that restore CD82 expression and inhibit

260 ages compared to more traditional anticancer drug therapies that typically rely on apoptosis.

261 al obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nat

262 tly approved, novel, mutation guided 'orphan drug' therapies that have established clinical benefits

263 ved in patients receiving optimal background drug therapy, that is, high doses of angiotensin-convert

264 bench experiments necessary to discover new drug therapies, the topic of molecular docking is core t

265 ntricular tachycardia despite antiarrhythmic drug therapy, there was a significantly lower rate of th

266 Antiepileptic drug therapy, though beneficial for restraining seizures

267 al to reduce adverse effects associated with drug therapy, tissue-specific delivery remains challengi

268 of distant tumor growth and (b) use adjuvant drug therapies to block key identified mediator(s) to su

269 There is an unmet need for drug therapies to improve recovery by promoting brain pl

270 Research is ongoing to develop drug therapies to manage osteoarthritis (OA) and articul

271 Finally, drug therapies to prevent/treat diarrheal disease can be

272 uld become the targets of future alternative drug therapies to slow down the spread of antibiotic res

273 volumes necessitating the need for effective drug therapies to support efforts in prevention and earl

274 and provide a molecular target for potential drug therapies to treat muscle pain.

275 be of significant use in the development of drug therapies to treat the many disorders where failure

276 leading many patients who could benefit from drug therapy to not take these drugs.

277 ults provide proof of principle that a novel drug therapy to treat AKI, and potentially other acute o

278 idence that the AR is a potential target for drug therapy to treat conditions associated with aberran

279 drug resistance may evolve: starting triple-drug therapy, treatment with a single dose of nevirapine

280 Combination drug therapies under development for cystic fibrosis cau

281 for determining the sensitivity of tumors to drug therapy, under the assumption that stem cell enrich

282 eriority of nanoparticle design over current drug therapies used to treat cancers, it is surprising h

283 d with an upregulation of SERCA, a potential drug therapy, using the same protocol.

284 d treatments across categories (for example, drug therapy vs. weight management) or combined categori

285 ul outcome with a combination of surgery and drug therapy was achieved.

286 The drug therapy was continued for six months post-operative

287 iveness of the cryoablation procedure versus drug therapy was determined at 12 months.

288 Nonsteroidal anti-inflammatory drug therapy was effective in reducing CME detected by a

289 .5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences

290 o increase in the risk of glaucoma requiring drug therapy was observed among current topiramate users

291 tective effect diminished progressively once drug therapy was stopped.

292 Trial drug therapy was titrated during the first 2 weeks of th

293 gous familial hypercholesterolemia on stable drug therapy were treated with subcutaneous 420 mg AMG 1

294 lic blood pressure >160 mm Hg despite triple drug therapy) were eligible for enrolment.

295 but also accurate diagnostics and monitoring drug therapies, which are critical in clinical and regul

296 Third-line antiepileptic drug therapies with sedating or anesthetic effects predi

297 tions for the rational design of combination drug therapies with the potential for synergistic intera

298 Three-drug therapy with bortezomib, dexamethasone, and an alky

299 y (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir.

300 Adjunctive local drug therapy with thermo-reversible green tea gel has sh